Xinhua Finance and Economics Shanghai, November 7th (Reporter Hu Jiefei) - At the 6th China International Import and Export Expo, research-oriented biopharmaceutical company Aibowei joined forces with its subsidiary Aierjian Aesthetics Third to enter the Expo. From "images" to "medicine boxes" and then to entering "medical insurance reimbursement forms", Aberville's innovative drugs are both witnesses and beneficiaries of the development of the Chinese market.
During an interview with reporters, Dong Lijun, Vice President and General Manager of Aberville China, stated that after ten years of deep cultivation in China, Aberville has entered the era of Aberville China 2.0. With the help of the high-level "big stage" of opening up to the outside world, Aberville will work with various partners such as the government, enterprises, academic units, and associations to jointly build, build, and share the medical innovation ecosystem, Jointly explore better ways to solve disease problems and fulfill the long-term commitment of "putting patients at the center".
This year is Aberdeen's third participation in the CIIE. In the previous two events, we brought many innovative products that were the world's first and China's first to the CIIE, and both of them achieved great results. "Dong Lijun said, for example, during the 2020 CIIE, Aberdeen brought two debut products, namely Ruifu (Upatini) and Weikelai (Vineca). These two products were not yet approved when they participated in the CIIE that year, but can only be approved after the CIIE that year, while Ruifu was approved in 2022. Afterwards, these two products were included in the national medical insurance program in January of this year.
It is worth mentioning that the approval of the above products largely depends on the "Chinese speed" and also benefits from the China International Fair. Taking Ruifu as an example, in 2022, it was approved with three indications within one and a half months, and these three indications were included in medical insurance in 2023; In 2023, this product was approved for four new indications, two of which were approved before the end of June, and the other two were approved before entering the Expo. That is to say, Ruifu currently has a total of 7 indications, covering rheumatoid arthritis, ankylosing spondylitis, radiation negative axial spinal arthritis, ulcerative colitis, Crohn's disease, etc. Within 20 months, 7 indications were approved, reflecting both the company's recognition of the Chinese market and its strong attractiveness.
Currently, the innovative drug market in China is experiencing new changes. In Dong Lijun's view, it is clear that Aberdeen is more deeply aware than ten years ago that China, as the world's second largest pharmaceutical market, has great potential for development. Currently, China is entering a stage of upgrading pharmaceutical consumption, and the adjustment of population structure has also brought new opportunities to innovative pharmaceutical companies.
In recent years, in the Huabu Bureau, we have seen that many pharmaceutical companies have achieved some expected results of increased layout while bringing more drugs to Chinese patients. At the time of its establishment, ABV only had three to four hundred people, and its products were relatively single, with relatively small revenue in China. However, we are constantly increasing our research and development investment. Currently, there are 200 R&D personnel, including other employees. Currently, ABV's Pharmaceuticals and Erjian Aesthetics have one There are over two thousand employees in total Dong Lijun said that since the second half of last year, more and more cross-border exchanges have strengthened Aberdeen's confidence in deep cultivation in China.
Dong Lijun said that in the future, ABV will continue to base itself in Shanghai and deeply cultivate China. With the help of the CIIE platform and spillover effects, we will bring more innovative products and treatment plans to China. At the same time, we are committed to bringing more Chinese clinical experience and knowledge to the world. Alberto plans to launch over 30 new products or indications in China by 2030, with nearly 70 ongoing and planned clinical research projects, fully accelerating the meeting of the huge clinical needs of Chinese patients.